Stock 4890 TSUBOTA LABORATORY INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tsubota Laboratory Incorporated

Equities

4890

JP3535700003

Biotechnology & Medical Research

Delayed Japan Exchange
Other stock markets
 09:02:45 2024-05-15 pm EDT 		5-day change 1st Jan Change
372 JPY -0.80% Intraday chart for Tsubota Laboratory Incorporated +4.75% +11.94%
2022 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
2022 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI

Valuation

Fiscal Period: March 2023
Capitalization 1 20,979
Enterprise Value (EV) 1 18,956
P/E ratio 236 x
Yield -
Capitalization / Revenue 22 x
EV / Revenue 19.9 x
EV / EBITDA 92,021,054 x
EV / FCF -503,822,916 x
FCF Yield -0%
Price to Book 10.7 x
Nbr of stocks (in thousands) 25,307
Reference price 2 829.0
Announcement Date 6/29/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023
Net sales 1 441 687 640 954
EBITDA - - - 206
EBIT 1 15 251 137 167
Operating Margin 3.4% 36.54% 21.41% 17.51%
Earnings before Tax (EBT) 1 3 255 201 144
Net income 1 3 201 153 90
Net margin 0.68% 29.26% 23.91% 9.43%
EPS 2 0.1344 8.944 6.760 3.520
Free Cash Flow - - - -37.62
FCF margin - - - -3.94%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 5/20/22 5/20/22 5/20/22 6/29/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period:
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 320 369 951 2,023
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -37.6
ROE (net income / shareholders' equity) - 43.6% 22.9% 6.68%
ROA (Net income/ Total Assets) - 19.5% 6.35% 4.87%
Assets 1 - 1,030 2,408 1,849
Book Value Per Share 2 14.80 26.30 32.90 77.10
Cash Flow per Share 2 17.00 27.10 51.90 85.50
Capex - - - 44
Capex / Sales - - - 4.61%
Announcement Date 5/20/22 5/20/22 5/20/22 6/29/23
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TSUBOTA LABORATORY INCORPORATED Stock Tsubota Laboratory Incorporated
+11.94% 61.81M
MODERNA, INC. Stock Moderna, Inc.
+29.77% 49.18B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.00% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+50.47% 40.37B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.85B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.68% 26.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.99% 18.71B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.22% 13.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.41% 12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.62% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4890 Stock
  4. Financials Tsubota Laboratory Incorporated
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW